Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid for C. difficile recurrence prevention
NCT05526807Terminated
- Sponsor
- Nottingham University Hospitals
- Start
- May 2019
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of ursodeoxycholic acid in Clostridioides difficile infection (CDI), sponsored by Nottingham University Hospitals. Primary endpoint: Tolerability to oral ursodeoxycholic acid at 6 weeks. Started May 2019; status: terminated.
02
Drugs
ursodeoxycholic acid
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT05526807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526807.